Lymphoma Newsletter - August 2026

LymphomaAugust 2026

Listen: Audio Summary of Key Highlights

Clinical briefing · tap to listen

0:00 / 2:52

Lymphoma — Monthly Compass

Aug 01–31, 2026 • Priority Updates • 3–5 minute read

A curated, practice-minded digest of what moved in lymphoma this month — regulatory signals, clinical development, and the most practice-relevant publications.

Built for oncologists

OncRef Curated Oncology Intelligence Layer

Key Highlights

Important Drug Publication Updates
- Journal of Clinical Oncology reported mosunetuzumab induction with response‑adapted polatuzumab vedotin plus obinutuzumab in untreated indolent B‑NHL, supporting a chemotherapy‑free frontline paradigm with step‑up dosing to mitigate immune toxicities.
- Blood published final Phase 1/1b soquelitinib data in T‑cell lymphomas, which the sponsor states support its ongoing registrational Phase 3 program in r/r PTCL.
Key Clinical Development Updates
- CAR‑T regulatory momentum accelerated as Allogene’s cemacabtagene ansegedleucel received FDA RMAT and Fast Track designations for first‑line consolidation in high‑risk LBCL following an ALPHA3 futility review, Lyell’s rondecabtagene autoleucel secured RMAT (2L LBCL) plus RMAT and Fast Track (3L+ DLBCL) with pivotal data and BLA targeted for 2027, and Caribou’s vispacabtagene regedleucel obtained RMAT, Fast Track, and Orphan designations with FDA alignment on the randomized ANTLER‑3 Phase 3 in 2L LBCL.
- ADC Therapeutics, following a pre‑sBLA meeting on the LOTIS‑5 confirmatory trial of ZYNLONTA plus rituximab in r/r DLBCL, is reassessing its regulatory path and planning additional FDA interactions including potential Breakthrough Therapy submissions based on LOTIS‑7 and MZL data, while AbelZeta received FDA IND clearance for dual‑antigen Prizlon‑cel with U.S. protocols targeting 3L+ post‑CAR‑T and 2L CAR‑T–naïve LBCL and Corvus continued enrollment in its registrational Phase 3 soquelitinib trial in r/r PTCL under Fast Track and Orphan Drug designations.
Emerging Themes & Macro-Trends
- Frontline chemo‑sparing strategies in indolent B‑NHL are advancing, with CD3xCD20/CD19xCD3 bispecifics used as induction with response‑adapted layering and the Phase 3 SOUNDTRACK‑F1 directly testing surovatamig plus rituximab versus R‑CHOP/R‑CVP/BR in untreated FL.
- Convergence of ADCs with T‑cell engagers and emergence of safer dual‑antigen CAR‑T designs are driving deeper responses in 2L+ DLBCL and enabling earlier‑line, outpatient‑capable delivery in LBCL.

FDA Approvals/Withdrawals

There are no press releases between 2026-08-01 and 2026-08-31 about lymphoma.

Clinical Development Regulatory Updates

Lyell Immunopharma reported that FDA granted rondecabtagene autoleucel (ronde‑cel) RMAT and Fast Track designations for adults with relapsed/refractory DLBCL (3L+) and RMAT in 2L LBCL; pivotal PiNACLE and PiNACLE‑H2H trials are ongoing. The company guided to pivotal data in mid‑2027 with a BLA submission planned in the second half of 2027. ¹. (globenewswire.com) (read more)
Corvus Pharmaceuticals said enrollment is ongoing in its registrational Phase 3 soquelitinib trial in relapsed/refractory PTCL and reiterated FDA Fast Track and Orphan Drug designations for the program. The company emphasized the lack of FDA‑approved agents in PTCL based on randomized trials. ². (globenewswire.com) (read more)
Allogene Therapeutics announced FDA granted RMAT and Fast Track designations to cemacabtagene ansegedleucel (cema‑cel) for first‑line consolidation in high‑risk LBCL following review of an interim futility analysis from the pivotal Phase 2 ALPHA3 study. The company highlighted rapid U.S. site activation and program momentum toward next updates in 2027. ³. (globenewswire.com) (read more)
Caribou Biosciences reported that vispacabtagene regedleucel (vispa‑cel) received FDA RMAT, Fast Track, and Orphan Drug designations for B‑cell non‑Hodgkin lymphoma. Caribou also noted it reached alignment with FDA on the design of its planned randomized, pivotal ANTLER‑3 Phase 3 trial in second‑line LBCL. ⁴. (globenewswire.com) (read more)
ADC Therapeutics disclosed it recently held a pre‑sBLA meeting with FDA to discuss the LOTIS‑5 confirmatory trial of ZYNLONTA plus rituximab in r/r DLBCL; following FDA feedback on benefit‑risk, the company is reassessing its regulatory path. ZYNLONTA remains available under U.S. accelerated approval for 3L+ DLBCL, and ADC plans additional FDA interactions including potential Breakthrough Therapy submissions based on LOTIS‑7 and MZL data. ⁵. (prnewswire.com) (read more)
AbelZeta announced FDA clearance of its IND for C‑CAR039 (prizloncabtagene autoleucel; Prizlon‑cel), a CD20/CD19 bispecific CAR‑T, for relapsed or refractory LBCL. The company, which regained global rights to C‑CAR039 in July 2026, is working with FDA to finalize U.S. protocols for 3L+ post‑CAR‑T and 2L CAR‑T‑naïve LBCL populations. ⁶. (prnewswire.com) (read more)
CancerNetwork covered FDA clearance of AbelZeta’s IND for prizlon‑cel (C‑CAR039) in r/r LBCL, outlining plans to study the therapy in 3L+ post‑CAR‑T and 2L CAR‑T‑naïve cohorts. The article cites the company’s press release and supporting clinical data. ⁷. (cancernetwork.com) (read more)
Corvus announced publication of final Phase 1/1b data for soquelitinib in T‑cell lymphomas in Blood and reiterated FDA Fast Track (r/r PTCL) and Orphan Drug (T‑cell lymphoma) designations. The company stated the data support its ongoing registrational Phase 3 PTCL program. ⁸. (globenewswire.com) (read more)

Major Conference Updates

Conference Information

Society of Hematologic Oncology (SOHO) 2026 Annual Meeting; George R. Brown Convention Center, Houston, Texas; September 9–12, 2026. (read more)
EHA 2026 Congress; Stockholm, Sweden; June 2026 (reported in August sources). Overall sentiment: lymphoma innovation is accelerating toward chemo-sparing, immune-engaging strategies in earlier lines, with combination regimens and safer dual‑antigen CAR‑T poised to broaden access. (read more)

Theme 1: Bispecifics are moving up front (chemo‑sparing in indolent B‑NHL)
- Significance: Frontline bispecific strategies aim to replace alkylator‑based chemoimmunotherapy in FL/indolent NHL, promising outpatient, step‑up dosing and prolonged remissions. (read more)
- Mechanism insights / clinical impact: CD3xCD20 bispecifics used as induction with response‑adapted layering of ADC/anti‑CD20 (mosunetuzumab then polatuzumab vedotin + obinutuzumab) support a chemotherapy‑free paradigm in untreated indolent B‑NHL, with immune toxicities mitigated by step‑up dosing. In parallel, the Phase 3 SOUNDTRACK‑F1 compares surovatamig (AZD0486, a CD19xCD3 T‑cell engager) + rituximab vs R‑CHOP/R‑CVP/BR, directly testing chemo substitution. (read more)
- Patient populations affected: Previously untreated FL and marginal zone lymphoma; global Phase 3 eligibility broadens access beyond tertiary centers. (read more)
Theme 2: ADC + bispecific combinations deepen responses in r/r DLBCL
- Significance: Non‑overlapping cytotoxic (ADC) and T‑cell–redirecting (bispecific) mechanisms are converging to raise response depth and durability beyond either class alone, positioning combinations for 2L+ DLBCL. (read more)
- Mechanism insights / clinical impact: ZYNLONTA (loncastuximab tesirine‑lpyl; CD19‑directed PBD ADC) + glofitamab (COLUMVI; CD20xCD3) in LOTIS‑7 show “most compelling” 2L+ data to date per sponsor, with infection prophylaxis integrated into protocols typical for glofitamab. Company plans Phase 3 and BTD submission in 2026. (read more)
- Patient populations affected: r/r DLBCL in 2L+ settings, including patients unsuitable for transplant or after prior therapies. (read more)
Theme 3: Dual‑antigen CAR‑T designs target safer, broader delivery
- Significance: Improved safety profiles may unlock outpatient administration and earlier‑line trials, expanding CAR‑T access and capacity planning. (read more)
- Mechanism insights / clinical impact: Rondecabtagene Autoleucel (Ronde‑cel; CD19/CD20 “OR‑gate” with CD62L+ enrichment) reported no Grade ≥3 CRS and low Grade ≥3 ICANS in >100 LBCL patients; pivotal timelines advance. AbelZeta’s C‑CAR039/Prizlon‑cel (CD20/CD19) received FDA IND, signaling U.S. re‑entry and trials spanning 3L+ post‑CAR‑T and 2L CAR‑T–naïve LBCL. (read more)
- Patient populations affected: LBCL in 2L and 3L+, including patients previously treated with CAR‑T, widening potential eligibility. (read more)
Theme 4: Precision progress in T‑cell lymphomas (ITK inhibition)
- Significance: R/R PTCL remains an area of high unmet need; oral targeted agents could shift beyond cytotoxic salvage. (read more)
- Mechanism insights / clinical impact: Soquelitinib (selective ITK inhibitor) final Phase 1 data published in Blood; registrational Phase 3 PTCL enrollment “on track,” leveraging ITK‑driven T‑cell reprogramming to balance efficacy and tolerability. (read more)
- Patient populations affected: Adult r/r PTCL; burden higher in parts of Asia and South America, underscoring global relevance. (read more)
Significance
- Expected clinical or translational readouts: LOTIS‑7 and LOTIS‑5 submissions to ASH 2026; additional Ronde‑cel data in 2H26; ongoing SOUNDTRACK‑F1 frontline FL study. (read more)
- Regulatory or policy implications: ADCT evaluating sBLA path and planning BTD; FDA IND clearance for Prizlon‑cel expands U.S. dual‑target CAR‑T pipeline. (read more)
- Potential shifts in standard of care: Chemo‑sparing frontline indolent NHL, ADC+bispecifics in 2L+ DLBCL, and safer dual‑antigen CAR‑T may reframe care pathways and infusion logistics. (read more)
- Strategic implications: Invest in outpatient‑capable infrastructure, infection‑prophylaxis protocols for TCE/ADC combos, and manufacturing scale for multi‑antigen CAR‑T; visibility builds into SOHO (Sept 9–12) as a catalyst forum. (read more)

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. With three years of follow-up in the STARGLO trial, the fixed-duration combination of glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) continues to demonstrate superior overall survival (median OS 25.5 vs 12.5 months) and progression-free survival compared to rituximab-GemOx for transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. Efficacy was particularly pronounced in the second-line setting and in high-risk subgroups, supporting Glofit-GemOx as a potential curative, off-the-shelf treatment. ()

📋 NCT04408638

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. The next-generation BCL-2 inhibitor sonrotoclax demonstrated rapid and durable responses as a monotherapy in heavily pretreated patients with relapsed/refractory mantle cell lymphoma, achieving a 52.4% overall response rate. The agent showed a manageable safety profile and efficacy in high-risk subgroups, including those with TP53 mutations, positioning it as a promising oral therapy for this patient population. ()

📋 NCT05471843

Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma. Exposure-response analyses for epcoritamab in patients with relapsed/refractory follicular lymphoma support the recommended 48 mg full dose, as higher exposure was associated with greater efficacy, with response rates potentially plateauing at this level. A 3-step step-up dosing regimen was shown to lower the frequency and severity of cytokine release syndrome (CRS), confirming the optimal dosing strategy for this agent. ()

📋 NCT03625037

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation. Modeling of data from the EPCORE NHL-1 and NHL-3 studies demonstrates that optimized step-up dosing regimens for epcoritamab, combined with intravenous fluids and dexamethasone prophylaxis, are adequate to mitigate the risk of Grade ≥2 cytokine release syndrome (CRS). The analysis supports the approved 2-step regimen for large B-cell lymphoma and the 3-step regimen for follicular lymphoma as effective safety strategies. ()

📋 NCT03625037

New Publications Related to Drugs in Clinical Trial Development

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial. The ACCESS trial, a prospective phase II study, demonstrated encouraging short-term outcomes for peripheral blood stem cell transplantation using highly mismatched (e.g., 6/8) unrelated donors with post-transplant cyclophosphamide. This suggests the approach is a promising and viable option for patients who lack a closely matched donor, warranting further investigation. ()

📋 NCT04904588

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial. In a Japan subgroup analysis of the phase III SUNMO trial, the combination of subcutaneous mosunetuzumab and polatuzumab vedotin demonstrated superior efficacy and a manageable safety profile compared to R-GemOx for patients with relapsed/refractory large B-cell lymphoma. This novel, fixed-duration outpatient therapy achieved a 100% response rate and significantly prolonged progression-free survival, positioning it as a promising new treatment option. ()

📋 NCT05171647

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm. This first-in-human phase 1 study of CD123-directed CAR T-cell therapy established a favorable safety profile in heavily pretreated patients with relapsed/refractory AML and BPDCN, including those who had prior allogeneic transplants. Although the overall complete remission rate was modest, the findings support further development of this therapeutic strategy, potentially through CAR T-cell design optimization and combination approaches. ()

📋 NCT02159495

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report. A phase 1/2 trial from the TACL consortium demonstrated that the oral proteasome inhibitor ixazomib can be safely combined with standard chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia. The regimen showed a promising early efficacy signal, achieving a 67% complete response rate among evaluable patients, supporting its further investigation in this high-risk population. ()

📋 NCT03817320

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial. The phase 3 E4512 trial concluded that adjuvant crizotinib does not improve disease-free survival in patients with surgically resected, early-stage ALK-positive NSCLC compared to observation. These findings indicate that crizotinib should not be recommended as an adjuvant therapy in this setting. ()

📋 NCT02201992

Model-informed optimal dose selection of golcadomide in combination with R-CHOP in patients with previously untreated aggressive B-cell lymphoma. Utilizing a model-informed drug development approach, this study identified an optimal dose of the oral CELMoD agent golcadomide (0.4 mg) for combination with R-CHOP in previously untreated aggressive B-cell lymphoma. This dose demonstrated higher target protein degradation and a positive exposure-response relationship for efficacy, providing a quantitative rationale for dose selection in line with the FDA's Project Optimus. ()

📋 NCT04884035

Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. This study validates a risk-stratified therapeutic approach for adults with Philadelphia chromosome-negative ALL, demonstrating that the integration of genetic markers and end-of-induction MRD assessment accurately allocates patients to either allogeneic transplant or chemotherapy. This strategy effectively identifies a favorable-risk subgroup (MRD-negative, no high-risk genetics) with a 3-year overall survival of 81%, refining treatment pathways for this disease. ()

📋 NCT04179929

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18). The CCTG LY.18 phase 1 trial established a manageable safety profile for adding venetoclax to the R-GDP salvage regimen for relapsed/refractory large B-cell lymphoma prior to autologous transplant. Despite this, the combination yielded a low complete response rate of 12.5%, suggesting that further development of this specific regimen is unlikely given the advent of more effective therapies. ()

📋 NCT04161248

Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma. Exposure-response analyses for epcoritamab in relapsed/refractory follicular lymphoma support the 48 mg full dose, as higher exposure correlated with greater efficacy without increased toxicity. The study also confirms that an optimized 3-step step-up dosing regimen effectively mitigates the frequency and severity of cytokine release syndrome. ()

📋 NCT04542824

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation. By employing repeated time-to-event modeling, this analysis demonstrates that optimized step-up dosing regimens for epcoritamab, combined with prophylactic measures such as IV fluids and dexamethasone, effectively mitigate the risk of clinically significant cytokine release syndrome. The findings validate the approved 2-step dosing for large B-cell lymphoma and the 3-step regimen for follicular lymphoma as safe and effective strategies. ()

📋 NCT04542824

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas. In a phase 1 trial for relapsed/refractory T cell lymphomas, the selective oral ITK inhibitor soquelitinib demonstrated a favorable safety profile and significant antitumor activity, with durable responses observed in 37% of patients who had received 1-3 prior lines of therapy. The mechanism of action is linked to beneficially modulating the tumor microenvironment by promoting Th1-skewing and reducing T cell exhaustion. ()

📋 NCT03952078

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. The combination of the bispecific antibody mosunetuzumab and the antibody-drug conjugate polatuzumab vedotin achieved high and durable complete remission rates (78.6%) in a phase 2 study of heavily pretreated, high-risk patients with relapsed/refractory mantle cell lymphoma who had failed prior BTK inhibitor therapy. This novel, outpatient, fixed-duration regimen demonstrated a manageable safety profile, positioning it as a highly effective new therapeutic strategy for this challenging patient population. ()

📋 NCT03671018

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial. The EPCORE NHL-2 trial demonstrates that adding the bispecific antibody epcoritamab to standard R-CHOP chemotherapy for newly diagnosed, high-risk large B-cell lymphoma (IPI 3-5) leads to exceptionally high response rates, with a complete response rate of 85%. These promising long-term follow-up data, showing an estimated 2-year PFS of 80%, support the ongoing phase 3 evaluation of this combination as a potential new standard of care. ()

📋 NCT04663347

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma. Long-term, 3-year follow-up data from the EPCORE NHL-2 trial show that first-line treatment with epcoritamab combined with bendamustine and rituximab induces deep and highly durable remissions in patients with follicular lymphoma. This regimen achieved a 96% complete response rate, with 87% of responders remaining in remission at 3 years, highlighting its potential to significantly improve long-term outcomes in this setting. ()

📋 NCT04663347

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial. The phase 3 BRUIN CLL-322 trial demonstrates that the fixed-duration combination of pirtobrutinib, venetoclax, and rituximab significantly improves progression-free survival compared to the standard venetoclax-rituximab doublet in patients with previously treated CLL. These results, which were consistent in patients previously exposed to covalent BTK inhibitors, establish this triplet regimen as a potential new standard of care for relapsed/refractory CLL. ()

📋 NCT04965493

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study. The phase 2 DISTINKT study reports that danburstotug, an anti-PD-L1 antibody, demonstrates robust and durable efficacy in patients with relapsed/refractory extra-nodal natural killer/T-cell lymphoma, a disease with limited options. The treatment achieved a 78.9% objective response rate and had a manageable safety profile, with high PD-L1 expression emerging as a potential predictive biomarker for response. ()

📋 NCT04414163

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer. This quantitative pharmacology analysis provides the rationale for the 400 mg starting dose of ribociclib in early breast cancer, which is lower than the dose used for advanced disease. The study identified key differences in drug pharmacokinetics and cardiac safety profiles between patient populations, confirming that the 400 mg dose optimizes the benefit-risk profile by reducing neutropenia and QTcF prolongation in the adjuvant setting. ()

📋 NCT01237236

Lipid Nanoparticle-Encapsulated mRNA-2752 Encoding Human OX40L, IL-23, and IL-36γ plus Durvalumab Induces an Immunostimulatory Effect within the Tumor Microenvironment in Patients with Advanced Solid Tumors. A phase 1 study of mRNA-2752, an intratumoral therapy encoding three immunostimulatory proteins, demonstrated manageable safety and antitumor activity, particularly when combined with durvalumab in patients with advanced, treatment-resistant solid tumors. The combination achieved a 17.9% objective response rate in CPI-resistant melanoma and successfully induced a sustained inflammatory response within the tumor microenvironment, supporting the potential of mRNA-based therapeutics in oncology. ()

📋 NCT03739931

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial. The prospective BMT CTN 1702 trial provides key evidence on donor selection, showing that transplant outcomes with haploidentical or mismatched unrelated donors are comparable to those with matched unrelated donors. These findings support the strategic use of alternative donors to expedite transplantation for patients who lack a fully matched donor, although umbilical cord blood was associated with inferior survival. ()

📋 NCT03904134

Decade-long persistence of CD19 CAR T cells in B cell lymphomas. This landmark study demonstrates the remarkable durability of CD19 CAR T-cell therapy, with detectable and functional CAR T-cells persisting for over a decade in patients with B-cell lymphomas. Long-term persisting cells evolved into a unique double-negative (CD4-CD8-), effector-memory-like phenotype, providing critical insights into the biology of long-term cancer immunosurveillance. ()

📋 NCT02030834

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study. In a phase 1b study, the combination of the bispecific antibody glofitamab with R-CHOP immunochemotherapy demonstrated a high complete metabolic response rate of 83.9% and promising durability in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. These encouraging results, along with a manageable safety profile, support the ongoing investigation of this combination in the first-line setting for diffuse large B-cell lymphoma. ()

📋 NCT03467373

Long-Term Outcomes of Second Allogeneic Transplantation Following CD7 CAR-T in Remission for T-Cell Acute Lymphoblastic Leukemia or Lymphoma. For patients with T-ALL/LBL who relapse after a first allogeneic transplant, this study shows that CD7 CAR T-cell therapy is highly effective at inducing deep remissions. Consolidating this remission with a second allogeneic transplant appears to be a feasible and promising strategy for achieving long-term survival, although the high rate of non-relapse mortality highlights a key area for future optimization. ()

📋 NCT04572308

Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials). In a long-term analysis of phase III trials, the IL-6 inhibitor olokizumab demonstrated sustained and clinically meaningful improvements across a range of patient-reported outcomes, including pain, physical function, and fatigue, for up to 106 weeks. These findings confirm the long-term benefits of olokizumab on quality of life for patients with rheumatoid arthritis who have had an inadequate response to methotrexate or TNF inhibitors. ()

📋 NCT03120949

Clinical Trials Summary

Number of Clinical Trials in lymphoma updated from 2026-08-01 to 2026-08-31:

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

Phase 4

Total

Enrolling by Invitation

Not Yet Recruiting

Recruiting

158

Available

Approved for Marketing

Active, Not Recruiting

106

Completed

Total

117

314

Phase 1 Clinical Trials within 3 Months of Primary Completion Date:

DRUG

NCTID

Status

Clinical Trial Name

Completion Date

JNJ-80948543, JNJ-75348780, JNJ-87801493

NCT06139406

ACTIVE_NOT_RECRUITING

A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)

2026-09-30

Cyclophosphamide, Doxorubicin Hydrochloride, Veliparib

NCT00740805

ACTIVE_NOT_RECRUITING

A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma

2026-10-22

[No Drug Info]

NCT06383338

RECRUITING

A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.

2026-11

Cyclophosphamide, Fludarabine, KITE-197

NCT06079164

ACTIVE_NOT_RECRUITING

A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects With Relapsed or Refractory Large B-cell Lymphoma

2026-11

Copanlisib, : Nivolumab

NCT03884998

ACTIVE_NOT_RECRUITING

A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination With PD-1 Antagonist Nivolumab in Patients With Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma

2026-11-04

Phase 2 Clinical Trials within 3 Months of Primary Completion Date:

DRUG

NCTID

Status

Clinical Trial Name

Completion Date

DZD8586

NCT06539195

COMPLETED

A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

2026-06-10

Gabapentin

NCT05064319

COMPLETED

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders: A Randomized, Double-blind, Placebo-controlled, Parallel-group, MRI Study

2026-07-31

Pembrolizumab

NCT04827862

COMPLETED

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

2026-08-03

CPI-613

NCT03793140

COMPLETED

A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6

2026-08-25

ACP-196 (acalabrutinib)

NCT02213926

ACTIVE_NOT_RECRUITING

An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

2026-09-06

Glofitamab, Rituximab, Vincristine, Cyclophosphamide, Tocilizumab, Doxorubicin, Prednisone

NCT04980222

ACTIVE_NOT_RECRUITING

A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

2026-09-30

: Rituximab, : Mosunetuzumab, : Rituximab and Hyaluronidase Human

NCT05886036

RECRUITING

NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial With Either Rituximab or Mosunetuzumab

2026-10-31

Phase 3 Clinical Trials within 3 Months of Primary Completion Date:

DRUG

NCTID

Status

Clinical Trial Name

Completion Date

: Rituximab, Fludarabine Phosphate, Cyclophosphamide, Ibrutinib

NCT02048813

ACTIVE_NOT_RECRUITING

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

2026-10-09

Phase 4 Clinical Trials within 3 Months of Primary Completion Date:

No phase 4 trials completing within the next three months.

NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.